We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Generics Global Group of Eight (G8) Industry Guide 2013-2022

Published: October 2018
Pages: 176
Code: 5540E38B2603F6039E98428CC9FF7772
Format: PDF
Publisher MarketLine
From Add to basket
$ 1,495.00
The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Questions Answered:
- What was the size of the G8 generics market by value in 2017?
- What will be the size of the G8 generics market in 2022?
- What factors are affecting the strength of competition in the G8 generics market?
- How has the market performed over the last five years?
- How large is the G8 generics market in relation to its regional counterparts?

Additonal Information

  • Essential resource for top-line data and analysis covering the G8 generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.
  • - The G8 countries contributed $1,75,638.2 million in 2017 to the global generics industry, with a compound annual growth rate (CAGR) of 7.3% between 2013 and 2017. The G8 countries are expected to reach a value of $2,25,943.9 million in 2022, with a CAGR of 5.2% over the 2017-22 period.
  • - Among the G8 nations, the US is the leading country in the generics industry, with market revenues of $1,02,919.9 million in 2017. This was followed by Japan and Germany, with a value of $25,218.0 and $17,343.3 million, respectively.
  • - The US is expected to lead the generics industry in the G8 nations with a value of $1,30,127.0 million in 2016, followed by Japan and Germany with expected values of $33,841.0 and $19,577.2 million, respectively.

Reasons to buy

Save time carrying out entrylevel research by identifying the size, growth, and leading players in the G8 generics market Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 generics market Leading company profiles reveal details of key generics market players’ G8 operations and financial performance Add weight to presentations and pitches by understanding the future growth prospects of the G8 generics market with five year forecasts by both value and volume Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country
Add to basket
  • Table of Contents
  • Introduction 14
  • What is this report about? 14
  • Who is the target reader? 14
  • How to use this report 14
  • Definitions 14
  • Group of Eight (G8) Generics 15
  • Industry Outlook 15
  • Generics in Canada 19
  • Market Overview 19
  • Market Data 20
  • Market Segmentation 22
  • Market outlook 23
  • Five forces analysis 25
  • Macroeconomic indicators 32
  • Generics in France 34
  • Market Overview 34
  • Market Data 35
  • Market Segmentation 37
  • Market outlook 38
  • Five forces analysis 40
  • Macroeconomic indicators 46
  • Generics in Germany 48
  • Market Overview 48
  • Market Data 49
  • Market Segmentation 51
  • Market outlook 52
  • Five forces analysis 54
  • Macroeconomic indicators 60
  • Generics in Italy 62
  • Market Overview 62
  • Market Data 63
  • Market Segmentation 65
  • Market outlook 66
  • Five forces analysis 68
  • Macroeconomic indicators 74
  • Generics in Japan 76
  • Market Overview 76
  • Market Data 77
  • Market Segmentation 79
  • Market outlook 80
  • Five forces analysis 82
  • Macroeconomic indicators 88
  • Generics in Russia 90
  • Market Overview 90
  • Market Data 91
  • Market Segmentation 93
  • Market outlook 94
  • Five forces analysis 96
  • Macroeconomic indicators 102
  • Generics in The United Kingdom 104
  • Market Overview 104
  • Market Data 105
  • Market Segmentation 107
  • Market outlook 108
  • Five forces analysis 110
  • Macroeconomic indicators 117
  • Generics in The United States 119
  • Market Overview 119
  • Market Data 120
  • Market Segmentation 122
  • Market outlook 123
  • Five forces analysis 125
  • Macroeconomic indicators 132
  • Company Profiles 134
  • Leading Companies 134
  • Appendix 174
  • Methodology 174
  • About MarketLine 175
  • List of Tables
  • Table 1: G8 generics industry, revenue($m), 2013-22
  • Table 2: G8 generics industry, revenue by country ($m), 2013-17
  • Table 3: G8 generics industry forecast, revenue by country ($m), 2017-22
  • Table 4: Canada generics market value: $ million, 2013-17
  • Table 5: Canada generics market volume: % of total pharma, 2013-17
  • Table 6: Canada generics market geography segmentation: $ million, 2017
  • Table 7: Canada generics market value forecast: $ million, 2017-22
  • Table 8: Canada generics market volume forecast: % of total pharma, 2017-22
  • Table 9: Canada size of population (million), 2013-17
  • Table 10: Canada gdp (constant 2005 prices, $ billion), 2013-17
  • Table 11: Canada gdp (current prices, $ billion), 2013-17
  • Table 12: Canada inflation, 2013-17
  • Table 13: Canada consumer price index (absolute), 2013-17
  • Table 14: Canada exchange rate, 2013-17
  • Table 15: France generics market value: $ million, 2013-17
  • Table 16: France generics market volume: % of total pharma, 2013-17
  • Table 17: France generics market geography segmentation: $ million, 2017
  • Table 18: France generics market value forecast: $ million, 2017-22
  • Table 19: France generics market volume forecast: % of total pharma, 2017-22
  • Table 20: France size of population (million), 2013-17
  • Table 21: France gdp (constant 2005 prices, $ billion), 2013-17
  • Table 22: France gdp (current prices, $ billion), 2013-17
  • Table 23: France inflation, 2013-17
  • Table 24: France consumer price index (absolute), 2013-17
  • Table 25: France exchange rate, 2013-17
  • Table 26: Germany generics market value: $ million, 2013-17
  • Table 27: Germany generics market volume: % of total pharma, 2013-17
  • Table 28: Germany generics market geography segmentation: $ million, 2017
  • Table 29: Germany generics market value forecast: $ million, 2017-22
  • Table 30: Germany generics market volume forecast: % of total pharma, 2017-22
  • Table 31: Germany size of population (million), 2013-17
  • Table 32: Germany gdp (constant 2005 prices, $ billion), 2013-17
  • Table 33: Germany gdp (current prices, $ billion), 2013-17
  • Table 34: Germany inflation, 2013-17
  • Table 35: Germany consumer price index (absolute), 2013-17
  • Table 36: Germany exchange rate, 2013-17
  • Table 37: Italy generics market value: $ million, 2013-17
  • Table 38: Italy generics market volume: % of total pharma, 2013-17
  • Table 39: Italy generics market geography segmentation: $ million, 2017
  • Table 40: Italy generics market value forecast: $ million, 2017-22
  • Table 41: Italy generics market volume forecast: % of total pharma, 2017-22
  • Table 42: Italy size of population (million), 2013-17
  • Table 43: Italy gdp (constant 2005 prices, $ billion), 2013-17
  • Table 44: Italy gdp (current prices, $ billion), 2013-17
  • Table 45: Italy inflation, 2013-17
  • Table 46: Italy consumer price index (absolute), 2013-17
  • Table 47: Italy exchange rate, 2013-17
  • Table 48: Japan generics market value: $ million, 2013-17
  • Table 49: Japan generics market volume: % of total pharma, 2013-17
  • Table 50: Japan generics market geography segmentation: $ million, 2017
  • Table 51: Japan generics market value forecast: $ million, 2017-22
  • Table 52: Japan generics market volume forecast: % of total pharma, 2017-22
  • Table 53: Japan size of population (million), 2013-17
  • Table 54: Japan gdp (constant 2005 prices, $ billion), 2013-17
  • Table 55: Japan gdp (current prices, $ billion), 2013-17
  • Table 56: Japan inflation, 2013-17
  • Table 57: Japan consumer price index (absolute), 2013-17
  • Table 58: Japan exchange rate, 2013-17
  • Table 59: Russia generics market value: $ million, 2013-17
  • Table 60: Russia generics market volume: % of total pharma, 2013-17
  • Table 61: Russia generics market geography segmentation: $ million, 2017
  • Table 62: Russia generics market value forecast: $ million, 2017-22
  • Table 63: Russia generics market volume forecast: % of total pharma, 2017-22
  • Table 64: Russia size of population (million), 2013-17
  • Table 65: Russia gdp (constant 2005 prices, $ billion), 2013-17
  • Table 66: Russia gdp (current prices, $ billion), 2013-17
  • Table 67: Russia inflation, 2013-17
  • Table 68: Russia consumer price index (absolute), 2013-17
  • Table 69: Russia exchange rate, 2013-17
  • Table 70: United Kingdom generics market value: $ million, 2013-17
  • Table 71: United Kingdom generics market volume: % of total pharma, 2013-17
  • Table 72: United Kingdom generics market geography segmentation: $ million, 2017
  • Table 73: United Kingdom generics market value forecast: $ million, 2017-22
  • Table 74: United Kingdom generics market volume forecast: % of total pharma, 2017-22
  • Table 75: United Kingdom size of population (million), 2013-17
  • Table 76: United Kingdom gdp (constant 2005 prices, $ billion), 2013-17
  • Table 77: United Kingdom gdp (current prices, $ billion), 2013-17
  • Table 78: United Kingdom inflation, 2013-17
  • Table 79: United Kingdom consumer price index (absolute), 2013-17
  • Table 80: United Kingdom exchange rate, 2013-17
  • Table 81: United States generics market value: $ billion, 2013-17
  • Table 82: United States generics market volume: % of total pharma, 2013-17
  • Table 83: United States generics market geography segmentation: $ billion, 2017
  • Table 84: United States generics market value forecast: $ billion, 2017-22
  • Table 85: United States generics market volume forecast: % of total pharma, 2017-22
  • Table 86: United States size of population (million), 2013-17
  • Table 87: United States gdp (constant 2005 prices, $ billion), 2013-17
  • Table 88: United States gdp (current prices, $ billion), 2013-17
  • Table 89: United States inflation, 2013-17
  • Table 90: United States consumer price index (absolute), 2013-17
  • Table 91: United States exchange rate, 2013-17
  • Table 92: Apotex, Inc.: key facts
  • Table 93: Mylan N.V.: key facts
  • Table 94: Mylan N.V.: key financials ($)
  • Table 95: Mylan N.V.: key financial ratios
  • Table 96: Novartis AG: key facts
  • Table 97: Novartis AG: key financials ($)
  • Table 98: Novartis AG: key financial ratios
  • Table 99: Sanofi SA: key facts
  • Table 100: Sanofi SA: key financials ($)
  • Table 101: Sanofi SA: key financials (€)
  • Table 102: Sanofi SA: key financial ratios
  • Table 103: Les Laboratoires Servier: key facts
  • Table 104: STADA Arzneimittel AG: key facts
  • Table 105: STADA Arzneimittel AG: key financials ($)
  • Table 106: STADA Arzneimittel AG: key financials (€)
  • Table 107: STADA Arzneimittel AG: key financial ratios
  • Table 108: Daiichi Sankyo Co Ltd: key facts
  • Table 109: Daiichi Sankyo Co Ltd: key financials ($)
  • Table 110: Daiichi Sankyo Co Ltd: key financials (¥)
  • Table 111: Daiichi Sankyo Co Ltd: key financial ratios
  • Table 112: Lupin Ltd: key facts
  • Table 113: Lupin Ltd: key financials ($)
  • Table 114: Lupin Ltd: key financials (Rs.)
  • Table 115: Lupin Ltd: key financial ratios
  • Table 116: Sawai Pharmaceutical Co Ltd: key facts
  • Table 117: Sawai Pharmaceutical Co Ltd: key financials ($)
  • Table 118: Sawai Pharmaceutical Co Ltd: key financials (¥)
  • Table 119: Sawai Pharmaceutical Co Ltd: key financial ratios
  • Table 120: Abbott Laboratories: key facts
  • Table 121: Abbott Laboratories: key financials ($)
  • Table 122: Abbott Laboratories: key financial ratios
  • Table 123: Krka, d. d., Novo mesto: key facts
  • Table 124: Krka, d. d., Novo mesto: key financials ($)
  • Table 125: Krka, d. d., Novo mesto: key financials (€)
  • Table 126: Krka, d. d., Novo mesto: key financial ratios
  • Table 127: Pfizer Inc.: key facts
  • Table 128: Pfizer Inc.: key financials ($)
  • Table 129: Pfizer Inc.: key financial ratios
  • Table 130: Teva Pharmaceutical Industries Limited: key facts
  • Table 131: Teva Pharmaceutical Industries Limited: key financials ($)
  • Table 132: Teva Pharmaceutical Industries Limited: key financial ratios
  • List of Figures
  • Figure 1: G8 generics industry, revenue($m), 2013-22
  • Figure 2: G8 Generics industry, revenue by country (%), 2017
  • Figure 3: G8 generics industry, revenue by country ($m), 2013-17
  • Figure 4: G8 generics industry forecast, revenue by country ($m), 2017-22
  • Figure 5: Canada generics market value: $ million, 2013-17
  • Figure 6: Canada generics market volume: % of total pharma, 2013-17
  • Figure 7: Canada generics market geography segmentation: % share, by value, 2017
  • Figure 8: Canada generics market value forecast: $ million, 2017-22
  • Figure 9: Canada generics market volume forecast: % of total pharma, 2017-22
  • Figure 10: Forces driving competition in the generics market in Canada, 2017
  • Figure 11: Drivers of buyer power in the generics market in Canada, 2017
  • Figure 12: Drivers of supplier power in the generics market in Canada, 2017
  • Figure 13: Factors influencing the likelihood of new entrants in the generics market in Canada, 2017
  • Figure 14: Factors influencing the threat of substitutes in the generics market in Canada, 2017
  • Figure 15: Drivers of degree of rivalry in the generics market in Canada, 2017
  • Figure 16: France generics market value: $ million, 2013-17
  • Figure 17: France generics market volume: % of total pharma, 2013-17
  • Figure 18: France generics market geography segmentation: % share, by value, 2017
  • Figure 19: France generics market value forecast: $ million, 2017-22
  • Figure 20: France generics market volume forecast: % of total pharma, 2017-22
  • Figure 21: Forces driving competition in the generics market in France, 2017
  • Figure 22: Drivers of buyer power in the generics market in France, 2017
  • Figure 23: Drivers of supplier power in the generics market in France, 2017
  • Figure 24: Factors influencing the likelihood of new entrants in the generics market in France, 2017
  • Figure 25: Factors influencing the threat of substitutes in the generics market in France, 2017
  • Figure 26: Drivers of degree of rivalry in the generics market in France, 2017
  • Figure 27: Germany generics market value: $ million, 2013-17
  • Figure 28: Germany generics market volume: % of total pharma, 2013-17
  • Figure 29: Germany generics market geography segmentation: % share, by value, 2017
  • Figure 30: Germany generics market value forecast: $ million, 2017-22
  • Figure 31: Germany generics market volume forecast: % of total pharma, 2017-22
  • Figure 32: Forces driving competition in the generics market in Germany, 2017
  • Figure 33: Drivers of buyer power in the generics market in Germany, 2017
  • Figure 34: Drivers of supplier power in the generics market in Germany, 2017
  • Figure 35: Factors influencing the likelihood of new entrants in the generics market in Germany, 2017
  • Figure 36: Factors influencing the threat of substitutes in the generics market in Germany, 2017
  • Figure 37: Drivers of degree of rivalry in the generics market in Germany, 2017
  • Figure 38: Italy generics market value: $ million, 2013-17
  • Figure 39: Italy generics market volume: % of total pharma, 2013-17
  • Figure 40: Italy generics market geography segmentation: % share, by value, 2017
  • Figure 41: Italy generics market value forecast: $ million, 2017-22
  • Figure 42: Italy generics market volume forecast: % of total pharma, 2017-22
  • Figure 43: Forces driving competition in the generics market in Italy, 2017
  • Figure 44: Drivers of buyer power in the generics market in Italy, 2017
  • Figure 45: Drivers of supplier power in the generics market in Italy, 2017
  • Figure 46: Factors influencing the likelihood of new entrants in the generics market in Italy, 2017
  • Figure 47: Factors influencing the threat of substitutes in the generics market in Italy, 2017
  • Figure 48: Drivers of degree of rivalry in the generics market in Italy, 2017
  • Figure 49: Japan generics market value: $ million, 2013-17
  • Figure 50: Japan generics market volume: % of total pharma, 2013-17
  • Figure 51: Japan generics market geography segmentation: % share, by value, 2017
  • Figure 52: Japan generics market value forecast: $ million, 2017-22
  • Figure 53: Japan generics market volume forecast: % of total pharma, 2017-22
  • Figure 54: Forces driving competition in the generics market in Japan, 2017
  • Figure 55: Drivers of buyer power in the generics market in Japan, 2017
  • Figure 56: Drivers of supplier power in the generics market in Japan, 2017
  • Figure 57: Factors influencing the likelihood of new entrants in the generics market in Japan, 2017
  • Figure 58: Factors influencing the threat of substitutes in the generics market in Japan, 2017
  • Figure 59: Drivers of degree of rivalry in the generics market in Japan, 2017
  • Figure 60: Russia generics market value: $ million, 2013-17
  • Figure 61: Russia generics market volume: % of total pharma, 2013-17
  • Figure 62: Russia generics market geography segmentation: % share, by value, 2017
  • Figure 63: Russia generics market value forecast: $ million, 2017-22
  • Figure 64: Russia generics market volume forecast: % of total pharma, 2017-22
  • Figure 65: Forces driving competition in the generics market in Russia, 2017
  • Figure 66: Drivers of buyer power in the generics market in Russia, 2017
  • Figure 67: Drivers of supplier power in the generics market in Russia, 2017
  • Figure 68: Factors influencing the likelihood of new entrants in the generics market in Russia, 2017
  • Figure 69: Factors influencing the threat of substitutes in the generics market in Russia, 2017
  • Figure 70: Drivers of degree of rivalry in the generics market in Russia, 2017
  • Figure 71: United Kingdom generics market value: $ million, 2013-17
  • Figure 72: United Kingdom generics market volume: % of total pharma, 2013-17
  • Figure 73: United Kingdom generics market geography segmentation: % share, by value, 2017
  • Figure 74: United Kingdom generics market value forecast: $ million, 2017-22
  • Figure 75: United Kingdom generics market volume forecast: % of total pharma, 2017-22
  • Figure 76: Forces driving competition in the generics market in the United Kingdom, 2017
  • Figure 77: Drivers of buyer power in the generics market in the United Kingdom, 2017
  • Figure 78: Drivers of supplier power in the generics market in the United Kingdom, 2017
  • Figure 79: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2017
  • Figure 80: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2017
  • Figure 81: Drivers of degree of rivalry in the generics market in the United Kingdom, 2017
  • Figure 82: United States generics market value: $ billion, 2013-17
  • Figure 83: United States generics market volume: % of total pharma, 2013-17
  • Figure 84: United States generics market geography segmentation: % share, by value, 2017
  • Figure 85: United States generics market value forecast: $ billion, 2017-22
  • Figure 86: United States generics market volume forecast: % of total pharma, 2017-22
  • Figure 87: Forces driving competition in the generics market in the United States, 2017
  • Figure 88: Drivers of buyer power in the generics market in the United States, 2017
  • Figure 89: Drivers of supplier power in the generics market in the United States, 2017
  • Figure 90: Factors influencing the likelihood of new entrants in the generics market in the United States, 2017
  • Figure 91: Factors influencing the threat of substitutes in the generics market in the United States, 2017
  • Figure 92: Drivers of degree of rivalry in the generics market in the United States, 2017
  • Figure 93: Mylan N.V.: revenues & profitability
  • Figure 94: Mylan N.V.: assets & liabilities
  • Figure 95: Novartis AG: revenues & profitability
  • Figure 96: Novartis AG: assets & liabilities
  • Figure 97: Sanofi SA: revenues & profitability
  • Figure 98: Sanofi SA: assets & liabilities
  • Figure 99: STADA Arzneimittel AG: revenues & profitability
  • Figure 100: STADA Arzneimittel AG: assets & liabilities
  • Figure 101: Daiichi Sankyo Co Ltd: revenues & profitability
  • Figure 102: Daiichi Sankyo Co Ltd: assets & liabilities
  • Figure 103: Lupin Ltd: revenues & profitability
  • Figure 104: Lupin Ltd: assets & liabilities
  • Figure 105: Sawai Pharmaceutical Co Ltd: revenues & profitability
  • Figure 106: Sawai Pharmaceutical Co Ltd: assets & liabilities
  • Figure 107: Abbott Laboratories: revenues & profitability
  • Figure 108: Abbott Laboratories: assets & liabilities
  • Figure 109: Krka, d. d., Novo mesto: revenues & profitability
  • Figure 110: Krka, d. d., Novo mesto: assets & liabilities
  • Figure 111: Pfizer Inc.: revenues & profitability
  • Figure 112: Pfizer Inc.: assets & liabilities
  • Figure 113: Teva Pharmaceutical Industries Limited: revenues & profitability
  • Figure 114: Teva Pharmaceutical Industries Limited: assets & liabilities

Keywords
;